GLP-1 and the Obesity Wave: what has to be true
A new drug class with a very large addressable market.
The thesis
GLP-1 drugs for diabetes and obesity have a large and expanding addressable market. The thesis is that the makers, their supply chains, and adjacent beneficiaries grow as access widens, while some food and medical-device categories face pressure.
What has to be true
- •GLP-1 demand keeps expanding as indications and access widen
- •Manufacturing capacity scales to meet demand without ceding share
- •Pricing and insurance coverage hold up enough to sustain margins
The chain of beneficiaries
What would invalidate it
- •A new entrant or generic compresses pricing and share faster than expected
- •Insurance coverage tightens, cutting real-world access and volume
- •Safety or efficacy data emerges that slows adoption
If you are playing this theme
A theme thesis is only useful if you watch the things that would break it. The invalidation triggers above are the events to monitor, and they show up in filings and earnings before they show up in the price. Helm tracks the pillars behind each name you hold and tells you, with a dated citation, when one weakens. It also flags when several of your holdings rest on the same theme, which is the concentration a position-by-position view hides. See how thesis monitoring works.
Common questions
What is the glp-1 and the obesity wave thesis?
GLP-1 drugs for diabetes and obesity have a large and expanding addressable market. The thesis is that the makers, their supply chains, and adjacent beneficiaries grow as access widens, while some food and medical-device categories face pressure.
What would invalidate the glp-1 and the obesity wave thesis?
A new entrant or generic compresses pricing and share faster than expected Insurance coverage tightens, cutting real-world access and volume Safety or efficacy data emerges that slows adoption
Which stocks are exposed to the glp-1 and the obesity wave theme?
The theme runs through a chain: Drug makers (LLY, NVO); Supply and devices (TMO).
Watch what would break the thesis.
Helm monitors the reasons behind every position you hold and tells you when one starts to break. Free to start.
Take the helmThis content is for educational purposes only and does not constitute financial, tax, or investment advice. Tickers are listed to illustrate a theme, not as recommendations. Helm Terminal is not a registered investment advisor.